Xylem, Inc. (XYL) Stock Price Today
Key Stats
- $27.87BMARKET_CAP
- -VOLUME
- IndustrialsSECTOR
- $152.95FIFTY_TWO_WEEK_HIGH
- $106.34FIFTY_TWO_WEEK_LOW
- -TYPICAL_HOLD_TIME
- $29.13BENTERPRISE_VALUE
- 1.47%DIVIDEND_YIELD
- -TRADING_ACTIVITY
Track Xylem, Inc. (XYL) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Xylem, Inc. has traded between a low of $106.34 and a high of $152.95, highlighting its annual price range. Buy and sell Xylem, Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Most Recent News
NIU Technologies reports 25% sales growth in China for Q2 2026, driven by new smart electric models.
In Q2 2026, NIU Technologies sold 434,687 electric mobility units, marking a 25% year-over-year increase in China with 402,202 units sold. Growth was fueled by strong demand for core and new smart electric models, including the NX 2026 long-range mot...

Crypto market faces sharp June correction amid macro uncertainty and institutional fund shifts.
In June 2026, the cryptocurrency market experienced a significant correction driven by macroeconomic factors, with Bitcoin and Ethereum prices dropping over 20%. Institutional investors pulled approximately $4.5 billion from U.S. spot Bitcoin ETFs, m...

Travere Therapeutics grows rapidly with FILSPARI in rare kidney diseases, backed by strategic moves and market advantages.
Travere Therapeutics has evolved into a commercial platform focused on rare kidney diseases, driven by strong sales of FILSPARI for IgA nephropathy (IgAN) and recent approval for FSGS. The company's high valuation reflects its rapid revenue growth, o...
